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Received July 29, 2011; accepted April 2, 2012AbstractBackground: Comprehensive data regarding in-hospital cardiovascular events of adults with confirmed 2009 influenza A (H1N1) (2009 H1N1)
infections are limited. The aim of this study was to determine the clinical characteristics, laboratory parameters, and electrocardiographic (ECG)
findings for adults with 2009 H1N1 infections and to assess the differences in these parameters among adult patients with and without in-hospital
cardiovascular events.
Methods: Seventy-one patients were enrolled from the 2009 H1N1 registry database (our hospital registry of confirmed 2009 H1N1 infection
during the year 2009) and divided according to the presence of in-hospital cardiovascular events. Six patients had cardiovascular events (CV
group) and 65 did not (NCV group).
Results: The CV group was more likely to be old (p ¼ 0.023). Regarding co-morbidities, underlying coronary heart disease (p ¼ 0.001),
congestive heart failure (p ¼ 0.001), diabetes (p ¼ 0.001), and hypertension (p ¼ 0.014) had significant influences on cardiovascular events. The
CV group was also more likely to have chest pain (p ¼ 0.034), dyspnea (p ¼ 0.045), higher leukocyte count (p ¼ 0.014), higher C-reactive
protein (p ¼ 0.010), higher glucose level (p ¼ 0.001), and higher N-terminal probrain natriuretic peptide level (p ¼ 0.010) than the NCV group.
In addition, the CV group had a significantly higher in-hospital mortality rate ( p ¼ 0.010) and cardiac mortality rate ( p ¼ 0.001) than the NCV
group. However, there were no significant differences in ECG findings between the two groups.
Conclusion: Our study demonstrated that the CV group had higher in-hospital and cardiac mortality rates than the NCV group. A meticulous
therapeutic approach should be considered for elderly patients with 2009 H1N1 infections having coronary heart disease, congestive heart
failure, diabetes, hypertension, and high levels of leukocyte count, hs-CRP, glucose, and NT-proBNP at the time of admission.
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During periods of epidemic influenza, numerous deaths and
serious complications occur frequently in vulnerable pop-
ulations with underlying chronic medical disorders such as
cardiovascular diseases.1e4 Although some reports suggest
links between the 2009 influenza A (H1N1) (2009 H1N1)
infection and cardiovascular deaths, data describing cardio-
vascular complications of the 2009 H1N1 infection are
limited.5,6 Moreover, a dearth of literature exists about the role
of influenza as a trigger of in-hospital cardiovascular events in
adult patients with the 2009 H1N1 infection.7
The aim of this study was to determine the clinical char-
acteristics, laboratory parameters, and electrocardiographic
(ECG) findings for adults with 2009 H1N1 infections; to
assess the differences in these parameters among adult patients
who had in-hospital cardiovascular events (CV group) and
those who did not (NCV group); and to assess the in-hospital
courses and mortality in the two groups.
2. Methods2.1. Study participantsStudy data were obtained from the 2009 H1N1 Samsung
Changwon Hospital registry database. We approached 71
consecutive patients >15 years of age who were admitted to
our hospital, a 720-bed referral center, for confirmed 2009
H1N1 infection between August 1 and December 31, 2009. A
total of 5805 patients visited our center during the study
period, and 2436 patients (42%) were tested positive for 2009
H1N1. Out of 850 adult patients who were >15 years of age,
71 (8.4%) were admitted to our hospital because of severe
symptoms of H1N1 infection. Among 71 enrolled patients, six
(8.3%) had cardiovascular events during index hospitalization
and 65 did not. Out of the six patients in the CV group, acute
myocardial infarction occurred in three patients (on the 5th,
4th, and 5th day after admission, respectively), paroxysmal
atrial fibrillation in two patients (on the 4th and 6th day after
admission, respectively), and acute myocarditis in one patient
(on the 6th day after admission) during index hospitalization.
Acute myocardial infarction was diagnosed according to the
American College of Cardiology and the American Heart
Association guidelines (patients with acute myocardial
infarction presented with typical chest pain with ST elevation
on ECG and elevated cardiac enzymes and significant nar-
rowing or plaque rupture on coronary angiogram), and acute
myocarditis was diagnosed by myocardial biopsy performed in
patients with acute chest pain, ECG changes, and elevation of
cardiac enzymes.
One patient with acute myocardial infarction died of
cardiac arrest with intractable ventricular tachycardia. Medical
records of patients with confirmed 2009 H1N1 infections were
retrospectively reviewed, including demographic information,
clinical manifestations, and laboratory and ECG findings. In
all patients, ECGs and laboratory studies were performed on
the first hospital day.Obese patients were defined as those with a body mass
index (BMI) of >30 kg/m2. Diabetes mellitus was defined as
a serum fasting glucose level 126 mg/dL, a history of dia-
betes mellitus, or current use of antidiabetic medications.
Hypertension was defined as repeated measurement of
systolic blood pressure 140 mmHg or diastolic blood
pressure 90 mmHg, or previous antihypertensive medication
treatment. Current smoking was defined as having smoked
cigarettes <1 year prior to admission. To determine the
severity of illness, the Acute Physiology and Chronic Health
Evaluation (APACHE) II score and Charlson comorbidity
index were determined in all patients within 24 hours of
admission. The protocol was approved by the Institutional
Review Board of the Samsung Changwon Hospital. The
recommendations of the revised version of the Declaration of
Helsinki were met.2.2. Microbiological studiesNasopharyngeal swab specimens or transtracheal secretions
were collected from each patient at the time of admission and
tested for the 2009 H1N1 infection, which was confirmed with
real-time reverse-transcriptase polymerase chain reaction
analysis (Bioneer Corp., Daejeon, Korea). Laboratory techni-
cians were blinded to patient identity and characteristics.2.3. ECGInitially, ECGs were read by two cardiologists who were
masked with respect to the status of patient illness. Two
additional cardiologists, each with 10 years of experience in
their field, reviewed the ECGs to determine the clinical
significance of the findings.2.4. N-terminal probrain natriuretic peptide assayBlood samples were obtained from the antecubital vein and
put into tubes containing lithium heparin, and then centri-
fuged. These samples were stored at e70C until further
analysis. Plasma N-terminal probrain natriuretic peptide (NT-
proBNP) levels were measured using an Elecsys proBNP
reagent kit (Roche Diagnostics, Indianapolis, IN, USA) and an
Elecsys 2010 (Roche Diagnostics, Indianapolis, IN, USA).
Laboratory technicians were blinded to patient identities and
characteristics.2.5. Statistical analysisStatistical analysis was performed using SPSS Pc þ 12.0
software (SPSS Inc., Chicago, IL, USA). Data for continuous
variables were given in terms of the median and interquartile
range (IQR). The ManneWhitney nonparametric U test was
used to compare continuous variables between the two groups
because of wide standard deviation, and a chi-square test was
used to compare the categorical variables. Differences were
considered statistically significant when p < 0.05.
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CV and NCV groups are compared in Table 1. There were no
significant differences in gender, BMI, obesity, and current
smoker status, underlying cerebrovascular disease, chronic
obstructive pulmonary disease, liver cirrhosis, and chronic
renal disease between the two groups. The CV group consisted
of older patients (median age, 64.5 vs. 50 years; p ¼ 0.023)
and had a significantly higher prevalence of coronary heart
disease (33% vs. 2%; p ¼ 0.001), congestive heart failure
(33% vs. 2%; p ¼ 0.001), diabetes mellitus (100% vs. 15%;
p ¼ 0.001), and hypertension (67% vs. 22%; p ¼ 0.014). Most
initial presentations of the CV and NCV groups were similar
between the two groups. However, there was a significantly
higher incidence of chest pain (50% vs. 15%; p ¼ 0.034) and
dyspnea (83% vs. 40%; p ¼ 0.045) in the CV group than in the
NCV group. There were no significant differences in systolic
and diastolic blood pressures and heart rate.3.2. Laboratory and ECG findingsThe laboratory and ECG findings for the CV and NCV
groups are compared in Table 2. There were no significantTable 1
Comparison of clinical characteristics between CV and NCV groups.
CV group (n ¼ 6)
Age (y)a 64.5 (57.5e84.0)
Male gender, n (%) 5 (83)
Body mass index (kg/m2)a 21.3 (20.1e24.8)
Obesity, n (%) 3 (50)
Diabetes mellitus, n (%) 6 (100)
Hypertension, n (%) 4 (67)
Current smoker, n (%) 1 (17)
Coronary heart disease, n (%) 2 (33)
Congestive heart failure, n (%) 2 (33)
Cerebrovascular disease, n (%) 0 (0)
COPD, n (%) 0 (0)
Liver cirrhosis, n (%) 0 (0)
Chronic renal disease, n (%) 2 (33)
Clinical presentation
Chest pain, n (%) 3 (50)
Dyspnea, n (%) 5 (83)
Fever/chills, n (%) 5 (83)
Cough/sputum, n (%) 6 (100)
Sore throat, n (%) 0 (0)
Nausea/vomiting, n (%) 1 (17)
Abdominal pain/diarrhea, n (%) 2 (33)
Headache, n (%) 0 (0)
Fatigue/myalgia, n (%) 3 (50)
Hemodynamic parameters
SBP (mmHg)a 145 (110e150)
DBP (mmHg)a 91 (62e103)
Heart rate (beats/min)a 101 (85e135)
*Significant finding.
COPD ¼ chronic obstructive pulmonary disease; CV group ¼ patients with cardiova
cardiovascular events; SBP ¼ systolic blood pressure.
a Presented as median (interquartile range).differences in ECG findings such as PR interval, QRS dura-
tion, or corrected QT interval. Also, there were no significant
differences in the prevalence of ST elevation, Q-wave, T-wave
inversion, first atrioventricular block, bundle branch block, and
atrial and ventricular premature beats.
The CV group had significantly higher blood levels of
leukocyte count (median, 15.1  103vs. 7.8  103/mL;
p ¼ 0.014), high sensitive C-reactive protein (hs-CRP)
(median, 153.4 vs. 54.5 mg/mL; p ¼ 0.010), and glucose
(median, 310.0 vs. 117.5 mg/dL; p ¼ 0.001) than the NCV
group. In addition, the CV group had significantly higher NT-
proBNP levels (median, 4756.0 vs. 480.0 pg/mL; p ¼ 0.010)
than the NCV group. However, there were no significant
differences in the leukocyte count, hemoglobin level, platelet
count, creatinine phosphokinase (CPK), lactate dehydrogenase
(LDH), albumin, blood urea nitrogen (BUN), creatinine,
creatinine phosphokinase-MB (CK-MB), and troponin-I blood
levels between the two groups.3.3. APACHE II score and Charlson comorbidity indexThe CV group had significantly higher APACHE II score
[median, 20.0 (IQR, 16.0e32.0) vs. 10.0 (IQR, 5.5e17.5);
p ¼ 0.001] and Charlson comorbidity index [median, 3 (IQR,
2e4) vs. 1 (IQR, 0e3); p ¼ 0.035] than the NCV group
(Fig. 1).NCV group (n ¼ 65) p
50.0 (28.5e66.0) 0.023*
31 (48) 0.102
22.4 (19.3e25.0) 0.950
17 (26) 0.204
10 (15) 0.001*
14 (22) 0.014*
15 (23) 0.719
1 (2) 0.001*
1 (2) 0.001*
16 (25) 0.237
5 (8) 0.485
2 (3) 0.665
5 (8) 0.041*
10 (15) 0.034*
26 (40) 0.045*
54 (83) 0.926
49 (75) 0.171
15 (23) 0.189
8 (12) 0.793
8 (12) 0.337
18 (28) 0.140
23 (35) 0.322
120 (105e140) 0.869
80 (60e90) 0.893
88 (76e109) 0.557
scular events; DBP ¼ Diastolic blood pressure; NCV group ¼ patients with no
Table 2
Comparison of electrocardiographic and laboratory findings between CV and NCV groups.
CV group (n ¼ 6) NCV group (n ¼ 65) p
Electrocardiographic changes
PR interval (ms)a 131.0 (118.0e196) 156.0 (144.0e176.0) 0.286
QRS duration (ms) 96.0 (91.0e132.0) 91.5 (86.0e99.0) 0.080
Corrected QT interval (ms) 461.0 (442.0e4932.0) 441.0 (424.0e468.8) 0.352
ST-segment elevation, n (%) 3 (50) 20 (31) 0.322
Q-wave, n (%) 1 (17) 2 (3) 0.110
T-wave inversion, n (%) 4 (67) 19 (29) 0.070
First AV block, n (%) 0 (0) 1 (2) 0.761
Bundle branch block, n (%) 1 (17) 2 (3) 0.110
Atrial premature beats, n (%) 1 (17) 2 (3) 0.110
Ventricular premature beats, n (%) 1 (17) 3 (5) 0.215
Laboratory findings
Leukocyte count (103/mL)a 15.1 (8.8e17.4) 7.8 (6.3e10.1) 0.032*
Lymphocyte count (%)a 11.2 (7.6e17.8) 12.7 (6.1e20.4) 0.854
Hemoglobin (g/dL)a 12.4 (9.5e14.9) 12.5 (11.1e14.4) 0.846
Platelet count (103/mL)a 194 (171e209.5) 182 (127.5e244) 0.575
hs-CRP (mg/mL)a 153.4 (71.2e259.3) 54.5 (15.5e120.4) 0.010*
CPK (ng/mL)a 143.0 (42.0e189.0) 98.0 (41.3e244.5) 0.665
LDH (ng/mL)a 322.0 (267.0e432.0) 226.0 (176.0e322.0) 0.102
Albumin (g/dL)a 3.0 (2.5e3.5) 3.1 (2.5e3.7) 0.721
Glucose (mg/dL)a 310.0 (210.0e420.0) 117.5 (106.3e135.5) 0.001*
BUN (mg/dL)a 15.7 (12.3e27.4) 10.0 (7.2e20.4) 0.082
Creatinine (mg/dL)a 1.5 (0.9e1.9) 0.9 (0.7e1.2) 0.081
CK-MB (ng/mL)a 3.5 (1.5e5.3) 2.6 (1.7e4.1) 0.821
Troponin-I (ng/mL)a 0.02 (0.01e0.08) 0.02 (0.01e0.04) 0.640
NT-proBNP (pg/mL)a 4756.0 (2405.0e13210.0) 480.0 (54.5e6704.3) 0.010*
* Significant finding.
AV ¼ atrioventricular; BUN ¼ blood urea nitrogen; CK-MB ¼ creatinine phosphokinase-MB; CPK ¼ creatinine phosphokinase; CV group ¼ patients with
cardiovascular events; hs-CRP ¼ high sensitive C-reactive protein; LDH ¼ lactate dehydrogenase; NCV group ¼ patients with no cardiovascular events;
NT-proBNP ¼ N-terminal probrain natriuretic peptide.
a Presented as median (interquartile range).
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groups are compared in Table 3. There were no significant
differences in the time intervals between the two groups, from
the duration of symptoms to the time of admission [median,
2.5 days (IQR, 1.0e5.0 days) in the CV group vs. median, 2.0
days (IQR, 0e4 days) in the NCV group; p ¼ 0.467] to the
time of antiviral therapy [median, 2.5 days (IQR, 2.0e6.0Fig. 1. The APACHE II score and Charlson comorbidity index in the CVand NCV g
(IQR, 16.0e32.0) vs. 10.0 (IQR, 5.5e17.5); p ¼ 0.001] and Charlson comorbidity i
APACHE ¼ Acute Physiology and Chronic Health Evaluation; CV group ¼ patient
with no cardiovascular events.days)] in the CV group vs. median, 3.0 days (IQR, 1.0e5.0
days) in the NCV group; p ¼ 0.814].
Also, there were no significant differences in the use of
inotropics and renal replacement therapy, and in the use and
duration of antiviral and antibiotic therapies between the two
groups. The CV group had a significantly higher prevalence of
ventilator use (33% vs. 8%; p ¼ 0.041), and a significantly
higher duration of ICU stay (median, 15 vs. 2 days; p ¼ 0.001)
and length of hospitalization (median, 23 vs. 6 days;roups. The CV group had significantly higher APACHE II score [median, 20.0
ndex [median, 3 (IQR, 2e4) vs. 1 (IQR, 0e3); p ¼ 0.035] than the NCV group.
s with cardiovascular events; IQR ¼ interquartile range; NCV group ¼ patients
Table 3
Comparison of clinical courses and management between CV and NCV groups.
CV group (n ¼ 6) NCV group (n ¼ 65) p
Use of antiviral therapy, n (%) 100 (0) 100 (0) d
Duration of antiviral therapy (d)a 5.0 (5.0e5.0) 5.0 (5.0e5.0) 0.880
Combined bacterial pneumonia, n (%) 3 (50) 35 (54) 0.831
Use of antibiotic therapy, n (%) 6 (100) 54 (84) 0.665
Duration of antibiotic therapy (d)a 10.0 (10.0e14.0) 7.0 (5.0e10.0) 0.118
Use of inotropics, n (%) 3 (50) 16 (25) 0.171
Use of renal replacement therapy, n (%) 0 (0) 2 (3) 0.748
Use of ventilator, n (%) 2 (33) 5 (8) 0.041*
ICU stay, n (%) 5 (83) 14 (22) 0.002*
ICU duration (d)a 15.0 (4.5e26.8) 2.0 (0.0e4.0) 0.001*
Hospitalization (d)a 23.0 (9.8e38.8) 6.0 (3.0e10.5) 0.025*
In-hospital mortality, n (%) 2 (33) 3 (5) 0.010*
In-hospital cardiac mortality, n (%) 1 (17) 0 (0) 0.001*
* Significant finding.
CV group ¼ patients with cardiovascular events; ICU ¼ intensive care unit; NCV group ¼ patients with no cardiovascular events.
a Presented as median (interquartile range).
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significantly higher in-hospital mortality rate (33% vs. 5%;
p ¼ 0.010) and in-hospital cardiac mortality rate (17% vs. 0%;
p ¼ 0.001) than the NCV group.
During hospitalization (median, 7.5 days; IQR, 3.5e11.8
days), five of 72 patients (6.9%) died; patient death was
caused by cardiac arrest with ventricular tachycardia, diabetic
ketoacidosis, massive gastrointestinal bleeding, hypoxemia,
and septic shock, respectively.
4. Discussion
Themain findings of this study were as follows. First, the CV
group consisted of older patients; had a higher prevalence of
underlying coronary heart disease, congestive heart failure,
diabetes mellitus, and hypertension; and had higher blood
levels of leukocyte count, hs-CRP, glucose, and NT-proBNP
than the NCV group. Second, the CV group had significantly
higher in-hospital and cardiac mortalities than the NCV group.
To the best of our knowledge, this is the first study to
investigate in detail the clinical characteristics, laboratory
parameters, and ECG findings of adult patients with 2009
H1N1 infections in South Korea.6,7
Overall, some clinical features of our study were similar to
those of earlier published studies in the literature.8e10 Most
cases presented with clinical features of acute respiratory
illnesses and radiographic confirmation of pneumonia.10e12 In
comparison with previous studies showing greater than one-
third of cases presenting with gastrointestinal symptoms,8e10
19 (27%) of our 71 cases presented with gastrointestinal
symptoms such as nausea, vomiting, abdominal pain, or
diarrhea. In our study, 18% of patients presented with chest
pain or discomfort. Bandt et al13 reported that 5e10% of their
patients experienced cardiac symptoms during acute influenza
infection.
A remarkable finding in our study was that a significant
proportion (69%) of adult patients with 2009 H1N1 infections
had abnormal ECG findings in the early stages after symptoms
showed up, although serum CK-MB and troponin-I bloodlevels were normal. According to previous studies, ECG
abnormalities have been recorded in up to 81% of patients
hospitalized with influenza14e17 and in 43% of cases in
the community where patients were not hospitalized.18
The possible explanation of any discrepancies between ECG
changes and cardiac enzymes in the early stages after symp-
toms occurred is that the nonspecific nature of the origin of
many of the ECG changes may be influenced by respiratory
alkalosis or fever, but not by the 2009 H1N1 virus itself.
In our study, there were no significant associations between
abnormal initial ECG findings and cardiovascular events
during index hospitalization. Previously published studies
found that ECG abnormalities were not associated with
cardiac injury markers or echocardiographic contractile
abnormalities.16,17,19,20 Our study confirms this finding, and
together, these observations suggest that ECG changes during
the early stages of 2009 H1N1 infections may not predict the
cardiovascular events during index hospitalization and hence
are clinically insignificant.
A study of previously healthy military recruits found that
six (15%) of 40 patients with influenza had abnormal ECG
findings, and all had regional myocardial dysfunction
confirmed by echocardiography.19 The CK-MB levels were
elevated in three of the patients. Such findings are consistent
with acute myocarditis and suggest a much higher risk than
observed in our study. In contrast, other recent studies17,20,21
found that most increases in CK levels seen during influenza
in ambulatory adults were likely of skeletal muscle origin and
acute viral myocarditis secondary to influenza was a very
uncommon complication, which are consistent with the find-
ings of the present study. According to the recently published
reports, adverse cardiovascular events occur in patients with
influenza through a number of mechanisms, including fever,
vasodilatation, hypovolemia, hypoxia, proinflammatory cyto-
kine elaboration, and procoagulant effects, as well as direct
cardiac injury such as myocarditis.2,20
In the present study, it is unclear how common asymptom-
atic cardiac involvement of influenza infection is, because
we did not perform systemic investigations such as
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cardiac biopsy in all patients. However, the prevalence of such
cardiac involvement has been reported to range from 0% to
53% of cases.22
In the present study, the incidence rate of cardiovascular
events during index hospitalization is 8.5%. According to
previous studies, cardiac changes associated with acute influ-
enza virus infection were found in 15e43% of ambulatory
patients and 14e75% of hospitalized patients.16,17,19,20 The
possible hypothesis for differences in incidence rate is that our
patients received antiviral therapy, which might have reduced
the likelihood of cardiac complications. Also, small sample
size and retrospective design of our study may further account
for those differences.
A recent analysis of individuals with health insurance
coverage provided by a large insurance company during a single
influenza season in the United States suggested a protective
effect of oseltamivir treatment for influenza against adverse
cardiac outcomes, such as unstable angina, myocardial infarc-
tion, arrhythmia, or congestive heart failure.23 A recently pub-
lished study has found that influenza vaccination improves the
clinical course of coronary artery disease and reduces the
frequency of coronary ischemic events in patients with opti-
mally treated coronary artery disease.24 Therefore, our results
may support the results of these studies, showing the importance
of early antiviral treatment in patients with severe 2009 H1N1
infections and the possible potential for influenza vaccinations
to reduce the number of cardiac fatalities.
Interestingly, in our study, the CV group had higher blood
levels of leukocyte count, hs-CRP, and NT-proBNP than the
NCV group. Recent experimental studies in mice demon-
strated that inoculation of H1N1 virus into a mouse athero-
sclerosis model resulted in heavy infiltration of atherosclerotic
plaques by inflammatory cells, as well as platelet aggregation
and thrombosis, which was an essential step in the evolution of
acute coronary syndrome.25e27 Based on these findings, we
reasoned that higher hs-CRP and NT-proBNP blood levels in
the CV group might be reflective of the role of influenza in
stimulating cardiac remodeling, with acute inflammation
altering endothelial function. Therefore, higher leukocyte
count, hs-CRP, and NT-proBNP blood levels may be useful in
predicting an increased risk of cardiovascular events during
hospitalization in adult patients with 2009 H1N1 infections.
In our study, the CV group had significantly higher
APACHE II score and Charlson comorbidity index than the
NCV group. These findings may support findings of previous
studies reporting numerous deaths and complications in
vulnerable populations with underlying chronic medical
disorders such as cardiovascular diseases.1e4
Notably, in the present study, the CV group had higher
in-hospital mortality and in-hospital cardiac mortality than the
NCV group. According to previously published studies,
influenza has historically been linked to cardiovascular
disease,1,2 and, based on epidemiological studies, cardiovascular
deaths have increased during influenza epidemics.3,4 A recent
systematic review of 39 studies reported consistent observa-
tional evidence of an influenza association with myocardialinfarction.4 Based on the consistent findings of these studies, in
addition to the results of the current study, we reasoned that the
possibility of influenzamyocarditis, exacerbation of pre-existing
coronary artery disease, or worsening of congestive heart failure
is associated with increased cardiovascular mortalities in
patients with 2009 H1N1 infections.
In the current study, the overall mortality rate (7%) was
similar to that in previous studies, which reported a mortality
rate of 7% in a US cohort of 272 hospitalized patients.9 In our
study, mortality associated with 2009 H1N1 infection itself was
3%: one patient died of uncontrolled hypoxemia and the other
died of uncontrolled septic shock. Causes of deaths in most
patients were associated with underlying diseases. Therefore,
we suggest that meticulous medical care, including cardiovas-
cular and pulmonary support, as well as antiviral and antibiotic
therapy for infections is critical for controlling themortality and
morbidity associated with 2009 H1N1 infections.4.1. Study limitationsThere were some limitations in the current study. First, this
was a retrospective design. The use of a retrospective medical
record review may have contributed to information bias.
However, to the best of our knowledge, this is the first study
investigating in detail the clinical characteristics, laboratory
parameters, and ECG findings in adult patients with 2009
H1N1 infections who had in-hospital cardiovascular events.
Second, because a small number of case patients may not
represent the full 2009 H1N1 influenza clinical spectrum, our
study may have lacked a sufficient number of participants to
compare the differences between the two groups, and so these
comparisons should be interpreted with caution. Third, in most
cases, we did not perform systemic investigations such as
echocardiogram, cardiac magnetic resonance imaging, or
pathology examination. Finally, we could not investigate
asymptomatic cardiac involvement in adult patients with 2009
H1N1 infections due to the study’s retrospective design.
In conclusion, the CV group had higher in-hospital
mortality rate than the NCV group. Old age, underlying
coronary heart disease, congestive heart failure, diabetes, and
hypertension; and high blood levels of hs CRP, glucose, and
NT proBNP were significantly common in the CV group.
Based on these findings, a meticulous therapeutic approach
should be considered for patients with 2009 H1N1 infections
with these risk factors at the time of admission.
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